Welcome to our dedicated page for Xenon Pharmaceut SEC filings (Ticker: XENE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company developing azetukalner and other ion channel modulators for epilepsy, major depressive disorder (MDD), bipolar depression (BPD), and pain. As a foreign private issuer incorporated in Canada and listed on The Nasdaq Global Market, Xenon uses SEC reports to disclose financial results, executive changes, and other material events.
Among the key documents available here are Form 8-K filings, which Xenon uses to report quarterly financial results, business updates, and corporate developments such as the appointment of its Chief Financial Officer and related employment and equity arrangements. These filings often reference the company’s Phase 3 clinical programs in focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS), MDD, and BPD, as well as its early-stage NaV1.7, Kv7, and NaV1.1 programs.
Investors can also review exhibits attached to 8-Ks, including press releases that summarize results of operations and financial condition, R&D spending, and cash runway expectations, along with risk-focused forward-looking statements. Additional filings detail governance and compensation matters, such as severance protections and equity inducement grants made under Xenon’s inducement equity incentive plans.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and are paired with AI-powered summaries that highlight key points, explain technical language, and help users quickly identify information about Xenon’s clinical pipeline, executive changes, and financial disclosures. Users can also locate information relevant to insider and equity-related activity through option and restricted share unit grant disclosures contained in the company’s current reports.
Filing: Schedule 13G/A by FMR LLC and Abigail P. Johnson reporting beneficial ownership in XENON PHARMACEUTICALS INC (CUSIP 98420N105). The statement reflects an event date of 06/30/2025 and signature dated 08/05/2025.
Holdings: Aggregate beneficial ownership is 8,824,363 shares, representing 11.5% of the class. On the cover data FMR LLC reports sole voting power of 8,824,348, sole dispositive power of 8,824,363, and zero shared voting/dispositive power. Abigail P. Johnson is reported with sole dispositive power of 8,824,363 and no voting power shown. The filing states the securities were acquired and are held in the ordinary course of business and not to change or influence control of the issuer. Exhibit 99 and Exhibit 24 (power of attorney) are referenced.
Form 3 overview: On 25 June 2025, Xenon Pharmaceuticals Inc. (XENE) filed an Initial Statement of Beneficial Ownership (Form 3) on behalf of newly disclosed officer Darren S. Cline, Chief Commercial Officer. The filing reports the event date as 23 June 2025 and confirms Mr. Cline’s Section 16 insider status.
Key disclosure: Both Table I (non-derivative holdings) and Table II (derivative holdings) state "No securities are beneficially owned,” meaning Mr. Cline presently holds zero shares or options of Xenon. No amendments, joint filings, or indirect ownership structures are noted. The document is therefore a procedural compliance filing rather than a transaction or compensation event and contains no financial metrics, option grants, or purchase details.
For investors, the absence of insider ownership could be interpreted as a lack of immediate equity alignment, but the filing primarily signals timely regulatory compliance following Mr. Cline’s appointment.